Slingshot members are tracking this corporate initiative:
Amygdala Neurosciences Licenses Substance Abuse Candidate GS-6637 from Gilead (GILD) for Undisclosed Sum
Slingshot Insights Explained
Strategic Initiative Date
Announcement Date: Feb 16, 2017 Projected Implementation: Q1, 2017 Relevance Tracked Until: Q1, 2018
Don’t see a project related to the strategic initiative you care about?
Related Keywords Substance Abuse, Gs-6637